about
TroVax Renal Immunotherapy Survival TrialSafety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLCTAC Versus TC for Adjuvant Breast CancerAdj TC + Herceptin Early Stage Breast CancerA Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsExpanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsIxabepilone + Carboplatin Metastatic Breast CancerPARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsStudy to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple MyelomaLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneSunitinib Non Small Cell Lung Cancer Patients Over 70Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate CancerA Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBCGemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsChemotherapy in Treating Women With Breast Cancer That Can Be Surgically RemovedProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate CancerFirst-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaLUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyThe BEACON Study (Breast Cancer Outcomes With NKTR-102)A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerEribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerSafety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsAvelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSA Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsTesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCA Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR GeneA Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)A Study to Identify Participants With Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene AberrationsA Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerA Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or RAn Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
P6153
Q58849103-0AC61D49-37CE-4175-9221-5621FA57730CQ61915595-FC0FCA0B-F643-4300-8C81-D1BA2B4CC6B1Q61917760-DBC48531-32B4-4FE1-88FE-35E4320B6EF1Q61917781-7126BB0D-1D03-4EB1-88C0-B082C3F7C527Q61920661-0884E203-5542-4272-8194-EA8D757A4D65Q61921025-A3AA7703-EB06-4673-A689-4F829F124E32Q61932780-D7A91EBC-55A1-4734-89FC-6B2001926927Q61938275-2E24F382-B100-4AF6-8E2B-935EC7EAFE1DQ61938289-D29C4795-6F09-47D0-ACDB-B05BDF7C185DQ61938484-B3EC4655-D07C-4E01-9BF2-031094196128Q61969377-1BB041C9-AD37-4EEF-8F0E-F461727D29C3Q61969570-B55DB855-DD4A-4A05-B206-76C77C7B260CQ61979804-979FEFF9-35EC-4578-BE32-A7C90BCE5B2EQ61981135-6D983DAE-DDE8-4D3B-87B9-4EF1C37AFD2AQ61981538-3F9E215E-4D47-43D3-A12F-809C99828A03Q62062312-78670889-E08F-47FF-A0E5-BAB45F1A8F92Q62110359-4F420BD9-BAF1-4659-B8A6-CAF7A3C3E3E9Q62110630-46B02673-A4F7-4C8C-8251-229B0F21D9F3Q62111035-15CD27F8-5012-41A3-8EF2-499F90CD4167Q62811412-CB6C4650-52B2-4DA3-B065-E396945DEC84Q63319075-71F0F8BD-07CE-4F7D-B875-DA1E2857BA37Q63319514-FB3F4A5B-50B9-47BA-BADB-68F30A3652ADQ63320307-F646F564-5196-404C-A7BE-A3E937ABB268Q63322087-ABD70E7C-51BB-4987-8994-9C3DBD80B0E6Q63322698-691BD62D-4A64-4C6A-ABEB-01655858899CQ63334832-4CBDBC85-41CC-4F64-A8D3-E0562FB74E0BQ63393796-58775EFE-7C38-4167-96BD-B192FEA35A06Q63398536-81225FCE-29C2-4347-8526-38B1FA4DC5CCQ63405227-D4C8784B-614D-42F5-9F56-48AAD9EB4621Q63534256-C64CDEFD-F22A-4E36-A660-38FD2D558614Q63571964-CD410977-A7A7-4D20-9E46-D8769EC1A6CDQ63572233-85EDA9A4-F516-4C18-AD4A-632CB0779F5CQ64123852-63FC6045-993A-4289-8842-8465A5C5AE09Q64150546-73255244-C290-4317-8B7F-AC62213D7A3EQ64171324-C6DB1F41-CD09-498A-9C6D-1E63FB7F96B9Q64216733-EAE1AAEE-CD5F-42AA-9C8E-5103607E8B52
P6153
description
healthcare organization in Williamsburg, United States
@en
name
Virginia Oncology Associates
@en
type
label
Virginia Oncology Associates
@en
altLabel
VOA
@en
prefLabel
Virginia Oncology Associates
@en
P131
P213
0000 0004 0482 3223
P2427
grid.478132.b
P3500
P625
Point (-76.740942 37.337607)